Incretin Effect on the Immunological Phenotype

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Graz
• Treatments: Incretins; Liraglutide; Saxagliptin

Criteria

Inclusion Criteria:

-healthy subjects or patients with type 1 diabetes

Exclusion Criteria:

• pregnancy

• treatment with GLP-1-Analoga (Liraglutide, Exenatide)

• treatment with DPP4-inhibitor (Sitagliptin, Vildagliptin, Saxagliptin)

• chronic disease including a long-term medication over 4 weeks per year (except type 1 diabetes)